Japan panel approves AstraZeneca's Evusheld COVID treatment
- Country:
- Japan
Japan's health ministry said on Monday that its panel of experts had agreed to approve manufacturing and sales of AstraZeneca's COVID-19 preventive treatment Evusheld.
Evusheld is designed to protect against COVID infection for at least six months, and has been deployed in many countries for people with compromised immune systems who see little or no benefit from vaccines.
ALSO READ
-
Japanese Lawmakers Visit India to See Worker Protection and Skills Projects in Action
-
Japan-Backed ILO Projects Help 23,000 Workers Gain Rights and Fight Child Labour
-
Riding the Waves: India's Surfing Olympic Dream
-
Japan's Economic Crossroads: Takaichi's Bold Moves Amidst Debt Concerns
-
Indian Judokas Train in Japan: A Pre-Asian Games Adventure
Google News